{"component": "definition", "props": {"groups": [{"size": 11, "snippet_links": [], "snippet": "means Population Viability Analysis;", "samples": [{"hash": "aizde25ZOBX", "uri": "https://www.moraywest.com/application/files/9115/8142/2148/Moray-west-s.36-consent-Decision-Notice-and-Conditions.pdf", "label": "www.moraywest.com", "score": 14.3032464981, "published": false}, {"hash": "15vZUiePbB8", "uri": "http://marine.gov.scot/sites/default/files/seagreen_-_recommendation_to_ministers_-_annex_d_-_bravo_development_decision_notice.pdf", "label": "Notice", "score": 13.9637231827, "published": false}, {"hash": "1xNHktAH5It", "uri": "http://marine.gov.scot/sites/default/files/seagreen_-_recommendation_to_ministers_-_annex_c_-_alpha_development_decision_notice.pdf", "label": "Notice", "score": 13.9637231827, "published": false}], "hash": "d163ac7b6a0190ffa361030f31a83099", "id": 1}, {"size": 4, "snippet_links": [], "snippet": "has the meaning set forth in Section 9.8(a)(i).", "samples": [{"hash": "guruHdLx0fp", "uri": "/contracts/guruHdLx0fp#pva", "label": "Common Stock Purchase Agreement (Ultragenyx Pharmaceutical Inc.)", "score": 27.9459266663, "published": true}, {"hash": "g8f4OnZ6Dy2", "uri": "/contracts/g8f4OnZ6Dy2#pva", "label": "License and Collaboration Agreement (Ultragenyx Pharmaceutical Inc.)", "score": 27.9459266663, "published": true}, {"hash": "jLhS74mWt83", "uri": "/contracts/jLhS74mWt83#pva", "label": "License and Collaboration Agreement (Ultragenyx Pharmaceutical Inc.)", "score": 27.6036968231, "published": true}], "hash": "2081658d236afc6355ec2743b0b89349", "id": 2}, {"size": 4, "snippet_links": [{"key": "viability-assessment", "type": "definition", "offset": [17, 37]}, {"key": "electricity-act", "type": "clause", "offset": [70, 85]}], "snippet": "means Population Viability Assessment; \u201cs.36\u201d means Section 36 of the Electricity Act 1989;", "samples": [{"hash": "euHq3Wv9LDy", "uri": "https://marine.gov.scot/sites/default/files/ms-00010231_marine_licence_decision_notice.pdf", "label": "Notice", "score": 22.8718795776, "published": false}, {"hash": "Nbu0xXzyvu", "uri": "https://www.gov.scot/binaries/content/documents/govscot/publications/foi-eir-release/2024/11-a/foi-202400434817/documents/eir-202400434817---information-released---annex-b/eir-202400434817---information-released---annex-b/govscot:document/EIR%2B202400434817%2B-%2BInformation%2BReleased%2B-%2BAnnex%2BB.pdf", "label": "www.gov.scot", "score": 19.5607376099, "published": false}, {"hash": "6IfHCaryhYc", "uri": "https://marine.gov.scot/sites/default/files/ms-00010230_marine_licence_decision_notice.pdf", "label": "marine.gov.scot", "score": 18.8971118927, "published": false}], "hash": "d9077deb36fac33f36d8e88c617a5b82", "id": 3}, {"size": 4, "snippet_links": [], "snippet": "has the meaning set forth in Section 5.7(a).", "samples": [{"hash": "8XxQElTBgLG", "uri": "/contracts/8XxQElTBgLG#pva", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2717323303, "published": true}, {"hash": "7QX0wINzbpz", "uri": "/contracts/7QX0wINzbpz#pva", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2142372131, "published": true}], "hash": "7c85f4889a147a4d28f3b520970725c3", "id": 4}, {"size": 3, "snippet_links": [{"key": "viability-assessment", "type": "definition", "offset": [19, 39]}], "snippet": "means a population viability assessment.", "samples": [{"hash": "3rRoEesosOP", "uri": "https://dfw.state.or.us/fish/CRP/docs/rogue_fall_chinook/Rogue_CHF_Plan_Final_Appendixes_1-11-13.pdf", "label": "dfw.state.or.us", "score": 6.5304584503, "published": false}, {"hash": "24tnpHq9XAd", "uri": "https://www.dfw.state.or.us/agency/commission/minutes/13/01_jan/Exhibit%20C_Attachment%204_%20Part%202_Conservation%20Plan%20Appendices.pdf", "label": "www.dfw.state.or.us", "score": 6.492128849, "published": false}, {"hash": "f5Xla4EzWH9", "uri": "https://www.dfw.state.or.us/fish/CRP/docs/rogue_fall_chinook/Rogue%20CHF%20plan%20-%20public%20review%20draft%20-%20appendixes%20(Apr%2025).pdf", "label": "www.dfw.state.or.us", "score": 6.1553730965, "published": false}], "hash": "d1c332d5557ddaa27a878f917c793bb5", "id": 5}, {"size": 3, "snippet_links": [{"key": "pharmacovigilance-agreement", "type": "definition", "offset": [19, 46]}, {"key": "dated-as-of", "type": "definition", "offset": [48, 59]}], "snippet": "means that certain Pharmacovigilance Agreement, dated as of November 7, 2023, by and between Austrian Sub and Purchaser.", "samples": [{"hash": "jv2ozS0945v", "uri": "/contracts/jv2ozS0945v#pva", "label": "Asset Purchase Agreement (HOOKIPA Pharma Inc.)", "score": 36.3867225647, "published": true}, {"hash": "7uEFbg5QsWl", "uri": "https://ir.hookipapharma.com/static-files/900097a5-2530-4575-b0e1-9ca93eccb2a9", "label": "ir.hookipapharma.com", "score": 20.3651313782, "published": false}, {"hash": "1Y6iY1IrucV", "uri": "https://ir.hookipapharma.com/static-files/27d84fad-5233-471f-b0e3-fe001f617149", "label": "ir.hookipapharma.com", "score": 20.3651313782, "published": false}], "hash": "2eba6243283cdf8b92c9359f33533e48", "id": 6}, {"size": 2, "snippet_links": [{"key": "agreement-to-be", "type": "clause", "offset": [28, 43]}, {"key": "in-accordance-with", "type": "clause", "offset": [56, 74]}], "snippet": "means the pharmacovigilance agreement to be established in accordance with clause 6(e).", "samples": [{"hash": "htB3prs8blo", "uri": "/contracts/htB3prs8blo#pva", "label": "Licence Agreement (Acadia Pharmaceuticals Inc)", "score": 35.1567420959, "published": true}, {"hash": "hZBvknQKiJ2", "uri": "/contracts/hZBvknQKiJ2#pva", "label": "Licence Agreement (Acadia Pharmaceuticals Inc)", "score": 27.1553726196, "published": true}], "hash": "d36bc9e7264289c42f49130351aa4551", "id": 7}, {"size": 2, "snippet_links": [{"key": "prior-to", "type": "definition", "offset": [23, 31]}, {"key": "the-\u2587", "type": "clause", "offset": [93, 98]}, {"key": "of-accounts", "type": "clause", "offset": [164, 175]}, {"key": "by-client", "type": "clause", "offset": [196, 205]}, {"key": "account-types", "type": "clause", "offset": [233, 246]}, {"key": "price-plans", "type": "definition", "offset": [251, 262]}, {"key": "the-production", "type": "clause", "offset": [264, 278]}, {"key": "the-pre", "type": "clause", "offset": [308, 315]}], "snippet": "is a process conducted prior to each production \u2587\u2587\u2587\u2587 cycle in Atlys(R) to initially validate the \u2587\u2587\u2587\u2587 cycle. Pre-verification billing is run against a small subset of accounts (50 to 200) defined by Client, which covers a mixture of account types and price plans. The production \u2587\u2587\u2587\u2587 cycle is completed once the pre-verification run has been approved.", "samples": [{"hash": "ggMb6HLiTcI", "uri": "/contracts/ggMb6HLiTcI#pva", "label": "Master Services Agreement (American Cellular Corp /De/)", "score": 18.0, "published": true}, {"hash": "19WqSQuRnBv", "uri": "/contracts/19WqSQuRnBv#pva", "label": "Master Services Agreement (Dobson Communications Corp)", "score": 18.0, "published": true}], "hash": "e49017e439468a4da3f05406650f769f", "id": 8}, {"size": 2, "snippet_links": [], "snippet": "has the meaning set forth in Section 1.122.", "samples": [{"hash": "hVoQY5tHVPg", "uri": "/contracts/hVoQY5tHVPg#pva", "label": "Product Rights Agreement (EyePoint Pharmaceuticals, Inc.)", "score": 34.3744010925, "published": true}, {"hash": "9Yl8bTBfBCX", "uri": "/contracts/9Yl8bTBfBCX#pva", "label": "Product Rights Agreement (Alimera Sciences Inc)", "score": 33.3744010925, "published": true}], "hash": "5438dd0669baf78b5e6da9b67914143d", "id": 9}, {"size": 2, "snippet_links": [{"key": "part-1", "type": "clause", "offset": [66, 72]}, {"key": "committed-obligations", "type": "clause", "offset": [90, 111]}], "snippet": "shall have the meaning given to such term in paragraph 19.1(a) of Part 1 of Schedule 6.1 (Committed Obligations);", "samples": [{"hash": "1q6ppzteIEu", "uri": "/contracts/1q6ppzteIEu#pva", "label": "Franchise Agreement", "score": 25.1704311371, "published": true}, {"hash": "cHlBHnvPlMQ", "uri": "/contracts/cHlBHnvPlMQ#pva", "label": "Franchise Agreement", "score": 24.1827507019, "published": true}], "hash": "909acc239f6b6fc95579bf0956276c33", "id": 10}], "next_curs": "ClASSmoVc35sYXdpbnNpZGVyY29udHJhY3RzciwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIMcHZhIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 59, "title": "PVA", "snippet": "means Population Viability Analysis;", "id": "pva", "examples": ["IDEAYA shall be responsible, in collaboration with Licensee, for global pharmacovigilance activities in accordance with the <strong>PVA</strong> and Applicable Laws, as further described in the <strong>PVA</strong>.", "In the event of any inconsistency between this Agreement and the <strong>PVA</strong>, the terms of this Agreement shall prevail, except that the <strong>PVA</strong> shall prevail with regard to pharmacovigilance matters."], "related": [["ami", "AMI", "AMI"], ["gpd", "GPD", "GPD"], ["dgsd", "DGS&D", "DGS&amp;D"], ["hcp", "HCP", "HCP"], ["cmr", "CMR", "CMR"]], "related_snippets": [], "updated": "2026-03-19T05:56:49+00:00"}, "json": true, "cursor": ""}}